Have a feature idea you'd love to see implemented?
Let us know!
LXEO Lexeo Therapeutics Inc.
Price (delayed)
$6.2
Market cap
$205.01M
P/E Ratio
0.35
Dividend/share
N/A
EPS
$17.54
Enterprise value
$55.14M
We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. By taking aim at the underlying genetic
Highlights
The EPS has surged by 189% since the previous quarter and by 143% year-on-year
The debt has contracted by 36% YoY and by 4.1% from the previous quarter
LXEO's equity has soared by 186% year-on-year but it is down by 16% since the previous quarter
The quick ratio has declined by 37% since the previous quarter
LXEO's net income is down by 30% YoY and by 12% QoQ
Key stats
What are the main financial stats of LXEO
Market
Valuations
Earnings
Shares outstanding
33.07M
Market cap
$205.01M
Enterprise value
$55.14M
Price to book (P/B)
1.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$86.44M
EBITDA
-$84.47M
Free cash flow
-$67.36M
Per share
Balance sheet
Liquidity
EPS
$17.54
Free cash flow per share
-$2.04
Book value per share
$4.21
Revenue per share
$0
TBVPS
$5.26
Total assets
$173.87M
Total liabilities
$34.54M
Debt
$10.4M
Equity
$139.33M
Working capital
$132.64M
Debt to equity
0.07
Current ratio
5.95
Quick ratio
5.98
Net debt/EBITDA
1.77
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.2%
Return on equity
-57.7%
Return on invested capital
-2,044.2%
Return on capital employed
-58.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LXEO stock price
How has the Lexeo Therapeutics stock price performed over time
Intraday
1.31%
1 week
-20.31%
1 month
-41.06%
1 year
-43.69%
YTD
-53.8%
QTD
-31.42%
Financial performance
How have Lexeo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$93.36M
Net income
-$86.6M
Gross margin
N/A
Net margin
N/A
The operating income has decreased by 36% YoY and by 14% from the previous quarter
LXEO's net income is down by 30% YoY and by 12% QoQ
Growth
What is Lexeo Therapeutics's growth rate over time
Valuation
What is Lexeo Therapeutics stock price valuation
P/E
0.35
P/B
1.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 189% since the previous quarter and by 143% year-on-year
LXEO's equity has soared by 186% year-on-year but it is down by 16% since the previous quarter
The P/B is 46% below the last 4 quarters average of 2.7
Efficiency
How efficient is Lexeo Therapeutics business performance
Lexeo Therapeutics's ROIC has plunged by 182% YoY and by 92% from the previous quarter
The ROA has soared by 60% YoY and by 6% from the previous quarter
Lexeo Therapeutics's return on equity has increased by 44% QoQ
Dividends
What is LXEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LXEO.
Financial health
How did Lexeo Therapeutics financials performed over time
Lexeo Therapeutics's current ratio has decreased by 37% from the previous quarter
The quick ratio has declined by 37% since the previous quarter
The debt is 93% less than the equity
LXEO's equity has soared by 186% year-on-year but it is down by 16% since the previous quarter
The debt to equity has soared by 170% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.